Hot Chips - Ranbaxy Laboratories
Jayashree / 27 Sep 2010
The scrips in this column have been recommended with a short-term investment horizon and carry high risk. So, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations
Ranbaxy Laboratories has a balanced revenue mix with the high-growth emerging markets contributing up to 56 per cent to sales and the developed markets contributing 44 per cent. During CY08, Daiichi Sankyo (DS) acquired a majority stake in the company. Due to the settlement-related income from Flomax and exclusivity in Valtrex, the operating margins on a consolidated basis are likely to witness good growth going ahead. Also, owing to several key FTFs (first to file) opportunities which are expected to deliver maximum contribution at the EBITDA level, the margins are likely to improve. The company continues to cooperate with the FDA authority and the Department of Justice for early resolution of the pending issues at its Paonta Sahib (Imposed Application Integrity Policy) and Dewas facility (cGMP issue). The stock can be looked at for gain in the short to medium-term perspective.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.